Oral Formulation Development of the Anti-Angiogenesis Drug D-4517.2 to Treat Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME)

D-4517.2 SC - Ashvattha Therap

Eylea (aflibercept intravitreal) - Bayer, Regeneron

Natacha Le Moan 1; David W. Culp 2; Lindsay Marjoram 2; Vishnu Dwadasi 1; Jeffrey Cleland 1

Apr 6, 2023